p16, Cyclin D1, Ki-67, and AMACR as Markers for Dysplasia in Barrett Esophagus

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Applied immunohistochemistry & molecular morphology (Print)

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PAI.0b013e318168598bPMID 18665038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alpha-methylacyl-CoA Racemase/P504S Overexpression in Colorectal Carcinoma is Correlated With Tumor Differentiation

  2007cited by this paper
• Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence

  2007cited by this paper
• Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas

  2007cited by this paper
• AMACR Immunostaining is Useful in Detecting Dysplastic Epithelium in Barrett's Esophagus, Ulcerative Colitis, and Crohn's Disease

  2006influential reference
• Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas

  2006cited by this paper
• Expression of α-methylacyl–coenzyme A racemase in dysplastic Barrett's epithelium

  2006cited by this paper
• Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence.

  2006cited by this paper
• Subcellular localization, modification and protein complex formation of the cdk‐inhibitor p16 in Rb‐functional and Rb‐inactivated tumor cells

  2006cited by this paper
• Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf‐1, p27, and PCNA in Barrett's esophagus

  2006cited by this paper
• Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.

  2006influential reference
• Is there a way for pathologists to decrease interobserver variability in the diagnosis of dysplasia?

  2005cited by this paper
• p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma

  2005cited by this paper
• p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.

  2005cited by this paper
• Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis: Evidence of Homozygous Deletion in Esophageal Noninvasive Precursor Lesions and Therapeutic Implications

  2005cited by this paper
• Prevalence of Barrett's esophagus in the general population: an endoscopic study.

  2005cited by this paper
• α-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis

  2005cited by this paper
• Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis.

  2004cited by this paper
• INK4a-ARF alterations in Barrett’s epithelium, intraepithelial neoplasia and Barrett’s adenocarcinoma

  2004cited by this paper
• Consistent Immunostaining for Cyclin D1 Can Be Achieved on a Routine Basis Using a Newly Available Rabbit Monoclonal Antibody

  2004cited by this paper
• 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.

  2003cited by this paper
• A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.

  2003cited by this paper
• A dietary enzyme: α-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma

  2003cited by this paper
• alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

  2002cited by this paper
• Update on grading dysplasia in barrett’s esophagus

  2002cited by this paper
• Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.

  2001influential reference
• P504S: A New Molecular Marker for the Detection of Prostate Carcinoma

  2001cited by this paper
• Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

  2001cited by this paper
• Long-term follow-up of Barrett's high-grade dysplasia

  2000cited by this paper
• Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.

  2000cited by this paper
• Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.

  2000cited by this paper
• Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.

  2000cited by this paper
• The diagnosis of dysplasia and malignancy in Barrett's oesophagus

  2000cited by this paper
• p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer.

  1999cited by this paper
• Etiology of Barrett's metaplasia and esophageal adenocarcinoma.

  1997cited by this paper
• Increased expression of the cyclin D1 gene in Barrett's esophagus.

  1996cited by this paper
• Expansion of the Ki‐67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus

  1995influential reference
• The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.

  1995influential reference
• Barrett's esophagus, dysplasia, and adenocarcinoma.

  1994influential reference
• Risk factors for the development of an adenocarcinoma in columnar‐lined (Barrett) esophagus

  1993cited by this paper
• Adenocarcinoma in Barrett's esophagus: a new epidemic?

  1992cited by this paper
• Barrett's esophagus: development of dysplasia and adenocarcinoma.

  1989cited by this paper
• Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

  1988influential reference
• Observer variation in the diagnosis of dysplasia in Barrett's esophagus.

  1988cited by this paper
• The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

  1985cited by this paper
• REVIEW ANNALS OF SURGERY

  year unknowncited by this paper

• The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett’s Esophagus–Dysplasia

  2024cites this paper
• Molecular biomarkers of progression from Barrett’s esophagus to esophageal adenocarcinoma

  2023cites this paper
• An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders.

  2023cites this paper
• A Consenus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.

  2022cites this paper
• Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression

  2021cites this paper
• Diagnosis and Surveillance of Barrett’s Esophagus

  2019cites this paper
• From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

  2019cites this paper
• Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa.

  2018cites this paper
• The Use of Ancillary Stains in the Diagnosis of Barrett Esophagus and Barrett Esophagus-associated Dysplasia: Recommendations From the Rodger C. Haggitt Gastrointestinal Pathology Society.

  2017cites this paper
• [Epigenetic markers of esophageal cancer: DNA methylation].

  2017cites this paper
• Meta‐analysis of biomarkers predicting risk of malignant progression in Barrett's oesophagus

  2017cites this paper
• IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus

  2017cites this paper
• Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma

  2016cites this paper
• From Barrett metaplasia to esophageal adenocarcinoma: the molecular background.

  2016cites this paper
• Healthcare Cost of Over-Diagnosis of Low-Grade Dysplasia in Barrett’s Esophagus

  2016cites this paper
• Genetics and Biomarkers in Barrett’s Esophagus and Esophageal Adenocarcinoma

  2016cites this paper
• Estudio de prevalencia, incidencia, supervivencia y factores de riesgo asociados al esófago de barrett y adenocarcinoma esofágico. Utilidad de los biomarcadores twist, p504s y cd133 en la valoración de la progresión del esófago de barrett

  2016cites this paper
• THE USE OF SPECIAL STAINS IN THE DIAGNOSIS OF BARRETT ESOPHAGUS AND BARRETT DYSPLASIA : RECOMMENDATIONS FROM THE RODGER C . HAGGITT GASTROINTESTINAL PATHOLOGY SOCIETY

  2016cites this paper
• Risk factors affecting the Barrett's metaplasia-dysplasia-neoplasia sequence.

  2015cites this paper
• Predictive value of immunohistochemistry in pre-malignant lesions of the gastrointestinal tract.

  2015cites this paper
• Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia

  2015cites this paper
• Problem ? Barrett ʼ s Neoplasia : Where is the Problem ?

  2014cites this paper
• Histopathology in Barrett Esophagus and Barrett Esophagus-Related Dysplasia

  2014cites this paper
• Biomarkers of Barrett's esophagus.

  2014cites this paper
• Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma.

  2014cites this paper
• Cyclin D 1 expression in Bowen ' s disease and cutaneous squamous cell carcinoma

  2014cites this paper
• Value of α‐methylacyl‐CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

  2013cites this paper
• Advanced precancerous lesions within the GI tract: the molecular background.

  2013cites this paper
• Gastrointestinal dysplasia

  2013cites this paper
• Early Diagnostic Biomarkers for Esophageal Adenocarcinoma—The Current State of Play

  2013cites this paper
• Barrett's oesophagus: epidemiology, cancer risk and implications for management

  2013cites this paper
• Predictive biomarkers for Barrett's esophagus: so near and yet so far.

  2013cites this paper
• Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments.

  2012cites this paper
• 18 – Esophageal Carcinoma

  2012cites this paper
• Upper Gastrointestinal Tract

  2011cites this paper
• Still waiting for predictive biomarkers in Barrett's oesophagus

  2011cites this paper
• American Gastroenterological Association technical review on the management of Barrett's esophagus.

  2011cites this paper
• Biomarkers in Barrett's Esophagus.

  2010cites this paper
• Usefulness of histopathological markers in diagnosing Barrett's intraepithelial neoplasia (dysplasia).

  2009cites this paper
• Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma

  2009cites this paper
• Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma

  2009cites this paper
• Alpha methyl acyl CoA racemase (AMACR)

  year unknowncites this paper